Due to the advent of novel agents such as proteasome inhibitors (PI), immunomodulatory agents (IMiD), and anti-CD38 monoclonal antibodies (MoAb), the survival of patients with multiple myeloma (MM) has improved and is expected to continue to improve (1, 2). The gene discussed is CD38; the disease is plasma cell myeloma.